Skip to main content

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum.

Saliva is a complex fluid containing various enzymes, hormones, antibodies, growth factors, enzymes and microbes reflecting the body’s health status. The saliva sample has the potential of being a diagnostic medium for a broad range of diseases, such as cancer and infectious agents, CMV, HIV, respiratory viruses (e.g., avian influenza viruses and coronaviruses) and bacterial infections; however, the low concentration of analytes and high concentration of PCR inhibitors have been challenges for assay developers.

Meridian’s new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes have been formulated specifically to overcome the inhibitors found in saliva samples, allowing a diagnosis directly from crudely processed saliva or sputum samples – no further optimization is required aside from the addition of primers and probes. Furthermore, these mixes can be used simply in a wet format or alternatively dried down to create ambient-temperature stable assays without the need for lyophilization.

Dr. Lourdes Weltzien, Executive Vice President – Life Science commented, “The use of Air-Dryable™ Direct qPCR Saliva mixes in the development of point-of-care assays, not only offer painless and quick sample analysis but also lower exposure risk to healthcare workers by reducing the need for sample handling. Our air-dryable technology has proven to save manufacturers’ time and cost, as well as allow them to control their entire manufacturing workflow.”

Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays. For more information on partnering with Meridian Bioscience, please visit https://meridianlifescience.com/air-dryable-mixes or email morey.setareh@meridianlifescience.com.

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.